Denali Therapeutics Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $-71.9M | $-78.0M | $6.1M | $3.0M |
| FY2017 | $-76.6M | $-79.5M | $2.9M | $4.4M |
| FY2018 | $50.1M | $46.7M | $3.4M | $18.8M |
| FY2019 | $-151.6M | $-169.5M | $17.9M | $38.4M |
| FY2020 | $416.2M | $413.1M | $3.1M | $50.4M |
| FY2021 | $-211.4M | $-219.9M | $8.5M | $85.2M |
| FY2022 | $-244.7M | $-262.5M | $17.8M | $99.8M |
| FY2023 | $-358.0M | $-370.9M | $12.9M | $108.1M |
| FY2024 | $-347.7M | $-363.6M | $15.9M | $102.9M |
| FY2025 | $-412.6M | $-422.1M | $9.5M | $99.6M |